Fluid biomarkers for disease activity in multiple sclerosis

Affiliations

¹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden/Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden/Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK/ UK Dementia Research Institute, London, UK.
² Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.

Editorial

Henrik Zetterberg et al. Mult Scler. 2017 Nov.

. 2017 Nov;23(13):1660-1661.

doi: 10.1177/1352458517736151. Epub 2017 Oct 6.

¹ Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden/Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden/Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK/ UK Dementia Research Institute, London, UK.
² Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.

No abstract available

Comment on

Defining active progressive multiple sclerosis.
Sellebjerg F, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermind LE, von Essen M, Ratzer RL, Soelberg Sørensen P, Romme Christensen J. Sellebjerg F, et al. Mult Scler. 2017 Nov;23(13):1727-1735. doi: 10.1177/1352458517726592. Epub 2017 Aug 23. Mult Scler. 2017. PMID: 28831853